Richet and Portier boarded Alberts ship Princesse Alice II for ocean exploration to make collections of the marine animals.Richet and Portier extracted a toxin called hypnotoxin from their collection of jellyfish (but the real source was later identified as Portuguese man o war) and sea anemone (Actinia sulcata). In their first experiment on the ship, they injected a dog with the toxin in an attempt to immunise the dog, which instead developed a severe reaction (hypersensitivity). In 1902, they repeated the injections in their laboratory and found that dogs normally tolerated the toxin at first injection, but on re-exposure, three weeks later with the same dose, they always developed fatal shock. They also found that the effect was not related to the doses of toxin used, as even small amounts in secondary injections were lethal. Thus, instead of inducing tolerance (prophylaxis) which they expected, they discovered effects of the toxin as deadly.In 1902, Richet introduced the term aphylaxis to describe the condition of lack of protection. He later changed the term to anaphylaxis on grounds of euphony. The term is from the Greek  ἀνά-, ana-, meaning "against", and φύλαξις, phylaxis, meaning "protection". On 15 February 1902, Richet and Portier jointly presented their findings before the Societé de Biologie in Paris. The moment is regarded as the birth of allergy (the term invented by Clemens von Pirquet in 1906) study (allergology). Richet continued to study on the phenomenon and was eventually awarded the Nobel Prize in Physiology or Medicine for his work on anaphylaxis in 1913.
The goal of these HELP groups was to provide a safe, confidential environment where participants can get accurate information and share experiences, fears, and feelings with others who are concerned about herpes. UK
In the UK, the Herpes Association (now the Herpes Viruses Association) was started in 1982, becoming a registered charity with a Dept of Health grant in 1985. The charity started as a string of local group meetings before acquiring an office and a national spread. Research
Research has gone into vaccines for both prevention and treatment of herpes infections. Unsuccessful clinical trials have been conducted for some glycoprotein subunit vaccines. As of 2017, the future pipeline includes several promising replication-incompetent vaccine proposals while two replication-competent (live-attenuated) HSV vaccine are undergoing human testing.A genomic study of the herpes simplex type 1 virus confirmed the human migration pattern theory known as the out-of-Africa hypothesis. References
External links

Herpes simplex at Curlie